http://en.wikipedia.org/wiki/Pseudogene#Processed
so, if you want to demonstrate your claim, you would need to write a script that showed that there was no pseudogene that ever inserted at a nonspecific site. You can't show that. ergo, my proposal is more likely than yours. Further, it's support by evidence- for example, the genome is studded with p53 pseudogenes that reintegrated from cDNA nonspecifically.
See the first 4 chapters of "Biology of Cancer" by Weinberg.
the work is mostly on okazaki fragments, but a major conclusion from my phd thesis was that B-RNA is stuck because of a very low probability event (the breaking of a large number of hbonds simultaneously).
http://scholar.google.com/citations?view_op=view_citation&hl...
http://scholar.google.com/citations?view_op=view_citation&hl...
http://scholar.google.com/citations?view_op=view_citation&hl...
http://scholar.google.com/citations?view_op=view_citation&hl...
Remember, the patent is a MOLECULE patent, not a PROCESS patent.
Anyway, your comment about oncogenes again shows you haven't read Biology of Cancer. if you read the first four chapters, it works out the history through which we worked out the understand of oncogenes. And the history is different from what we know now to be the prevalent mechanisms. The use of tumor viruses, which is nicely explained, demonstrates that scientists had already described the phenomenon I'm cited in the mid-1970's. That phenomenon wasn't really followed up on after the mid-80s, when people got better mechanisms and a larger understanding of cancer. But if you go back to the tumor virus literature and really understand it at a fundamental level, you have to acknowledge that BRCA cDNAs identical to the Myriad patent have almost certainly existed in both free (nucleoplasm) and integrated forms in at least one cell in the past. Whether that cell survived, is irrelevant.
Finally, if you think an existence proof is going to break a patent, I wish you luck in your future pursuits in life.
In fact DNA intermediates with introns spliced can be reintegrated into the genome.
Further, faulty viruses can acquire oncogenes (intron-splicted, mtuated versions of growth factors, like EGF and HER2/neu) and transfer them to other cells via cDNA intermediates. It's not hard to believe that nature has in fact passed BRCA cDNAs around via retroviral intermediates.